Last reviewed · How we verify

NCT04407117

Appendicitis During the National Lockdown During the COVID-19 Pandemic

Completed Last updated 19 June 2020
What this trial tests

trial testing Lock-down and social distancing in Appendicitis in 6,000,000 participants. Completed in 19 April 2020.

Timeline
23 March 2017
Primary endpoint
19 April 2020
19 April 2020

Quick facts

Lead sponsorClaus Anders Bertelsen, PhD, MD
StatusCompleted
Study typeOBSERVATIONAL
Enrollment6,000,000
Start date23 March 2017
Primary completion19 April 2020
Estimated completion19 April 2020
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Claus Anders Bertelsen, PhD, MD

Who can join

Eligibility, any sex, with Appendicitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to examine whether a nationwide lock-down with an entire population subjugated to social distancing reduces the incidence of appendicitis. If a reduction is detected it supports the hypothesis that infectious disease may play a role in the etiology of appendicitis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Incidence of appendicitis during COVID-19 lockdown: A nationwide population-based study.
    Jantzen AT, Bang-Nielsen A, Bertelsen CA, Torp-Pedersen C, et al · · 2022 · cited 3× · PMID 35488422 · DOI 10.1177/14574969221089387

Verify or expand the search:

Other recruiting trials for Appendicitis

Currently open trials in the same condition.

Other Claus Anders Bertelsen, PhD, MD trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04407117.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing